Bristol Myers Squibb Company $BMY Stock: Heritage Investors Management Corp Cuts Position

Heritage Investors Management Corp decreased its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 8.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 112,215 shares of the biopharmaceutical company’s stock after selling 9,907 shares during the quarter. Heritage Investors Management Corp’s holdings in Bristol Myers Squibb were worth $7,002,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Davis Asset Management L.P. bought a new position in Bristol Myers Squibb in the 2nd quarter worth $27,000. Addison Advisors LLC purchased a new position in shares of Bristol Myers Squibb in the second quarter worth $32,000. William Mack & Associates Inc. bought a new position in shares of Bristol Myers Squibb during the third quarter worth $35,000. Groupe la Francaise boosted its position in shares of Bristol Myers Squibb by 562.9% during the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 501 shares during the last quarter. Finally, Kilter Group LLC purchased a new position in Bristol Myers Squibb during the second quarter valued at $35,000. 76.41% of the stock is owned by hedge funds and other institutional investors.

Bristol Myers Squibb Trading Down 0.0%

BMY opened at $62.46 on Monday. The stock has a 50-day moving average of $62.80 and a 200 day moving average of $59.94. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. Bristol Myers Squibb Company has a 12 month low of $45.20 and a 12 month high of $68.64. The firm has a market cap of $127.67 billion, a P/E ratio of 13.85, a P/E/G ratio of 0.32 and a beta of 0.20.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.25. The business had revenue of $13.07 billion for the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.63 earnings per share. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.40 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.0%. Bristol Myers Squibb’s payout ratio is currently 55.88%.

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Cantor Fitzgerald cut their price objective on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating for the company in a research report on Thursday, October 8th. Roth Capital assumed coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating and a $75.00 price target for the company. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 13th. Zacks Research cut Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 22nd. Finally, Guggenheim reiterated a “buy” rating and set a $75.00 target price (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $65.46.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb reported third-quarter adjusted EPS of $1.35 and revenue of $13.07 billion, exceeding consensus estimates of $1.10 and $12.72 billion, respectively. Revenue increased 6.9% year over year. Bristol Myers Squibb Q3 revenue report
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to approximately $50 billion as its Growth Portfolio—including newer drugs—grew 12% to $7.7 billion, helping offset pressure from older products facing patent expirations. BMY Q3 earnings call highlights
• Positive Sentiment: Barclays maintained its Buy rating, while management pointed to pipeline progress, cancer-trial data and increased use of artificial intelligence in drug research as potential longer-term catalysts. Barclays maintains Buy rating
• Neutral Sentiment: The improved sales outlook is largely a revenue story: deal-related and higher in-process research and development charges contributed to a reduction in 2026 EPS guidance, and adjusted earnings fell from $1.63 a year earlier to $1.35. BMY earnings and guidance report
• Negative Sentiment: Opdivo sales came in below expectations, highlighting launch execution risks and the continuing challenge of replacing revenue from aging blockbuster drugs. Bristol Myers Opdivo sales report
• Negative Sentiment: Morgan Stanley cut its price target from $41 to $40 and reiterated an Underweight rating, implying substantial downside from the current trading level. Morgan Stanley BMY rating
• Negative Sentiment: A separate analysis downgraded BMY, arguing that progress from newer medicines may not fully overcome the company’s upcoming patent cliffs. Bristol Myers patent-cliff analysis

Bristol Myers Squibb Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.